ClinicalTrials.gg
CompletedNCT00973479Updated Dec 25, 2013Results posted

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

A Phase 3 interventional study of Golimumab and Placebo in Arthritis, Rheumatoid, sponsored by Centocor, Inc.. Completed at 91 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-25.

Sponsored by Centocor, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
592
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing golimumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. golimumab · Arthritis, Rheumatoid.

Enrollment
4th of 16
592 · median 356
Started
2009
with 2 others
Phase 3
11 of 16
1 open now
Registered
8th of 16
by date
Lead sponsor
8 of 16
Centocor, Inc.

Among the 16 studies testing golimumab in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 8th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 16 studies testing golimumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About golimumab

golimumab: first FDA approval 2009 (SIMPONI), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing golimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate clinical effectiveness and safety of golimumab with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) when compared to MTX alone.

Read the detailed description

This is a randomized (study medication is assigned by chance), double-blind (neither physician nor participants knows the treatment that the participant receives), placebo-controlled (an inactive substance is compared with a medication to test whether the medication has a real effect in a clinical study), multicenter, 2-arm (2 groups) study of golimumab in participants with active RA despite concurrent MTX therapy. Approximately 564 participants will be randomly allocated to 1 of 2 treatment groups in a 2:1 ratio ie, Group 1(approximately 376 participants will receive golimumab + MTX) and Group 2 (approximately 188 participants will receive MTX + placebo). Total duration of study for each participant is 112 weeks. Safety will be evaluated by assessment of adverse events, tuberculosis testing and blood testing.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • Arthritis, Rheumatoid
  • Active rheumatoid arthritis
  • Golimumab
  • CNTO148
  • Anti-TNFalpha monoclonal antibody
  • Methotrexate
  • Intravenous
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of rheumatoid arthritis (RA) for at least 3 months prior to screening
  • Have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg/week for at least 3 months prior to screening, and have been on a stable MTX dose of 15 mg/week to 25 mg/week for at least 4 weeks prior to screening
  • Have an active RA, as defined by disease activity with at least 6 swollen and 6 tender joints, at the time of screening and at baseline
  • C-Reactive Protein greater than or equal to 1.0 mg/dL at screening
  • No history of latent or active tuberculosis prior to screening

Exclusion criteria

Exclusion Criteria:

  • Other inflammatory diseases, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or lyme disease
  • Treated with disease modifying agents (other than methotrexate)/systemic immunosuppressives (eg, D-penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold, sulfasalazine, leflunomide, azathioprine, cyclosporine, mycophenolate mofetil) during the 4 weeks prior to first administration of study agent
  • Received intra-articular (in the joint), intramuscular (in the muscle), or intravenous , including adrenocorticotropic hormone, during the 4 weeks prior to first administration of study agent
  • Known allergy to human immunoglobulin proteins or other components of golimumab
  • Received any commercial or anti-tumor necrosis factor alpha therapy such as but not exclusively infliximab, golimumab, adalimumab or etanercept
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
592 participants (actual)

Study arms

  • Experimental
    Group I: Placebo + Methotrexate (MTX)

    Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.

    Drug: Golimumab · Other: Placebo · Drug: methotrexate (MTX)

  • Placebo comparator
    Group II: Golimumab + Methotrexate (MTX)

    Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.

    Drug: Golimumab · Other: Placebo · Drug: methotrexate (MTX)

Interventions

  • Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).

  • OtherPlacebo

    Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.

  • Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14

    An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 20 percentage improvement in at least 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS), (0 \[no pain\] to 10 \[worst pain\]) b. Participant's global assessment of disease activity by VAS c. Physician's global assessment of disease activity by VAS d. Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C-reactive protein.

    Time frame: Week 14

Secondary outcomes

  1. Proportion of Participants With Moderate or Good Response in Disease Activity Index Score 28 (DAS28) Using C-reactive Protein (CRP) at Week 14

    DAS28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis combining tender joints (28 joints), swollen joints (28 joints), CRP, and participant's global assessment of disease activity. The DAS28 score ranges from 0 (best) to 10 (worst). DAS28 score above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. Higher scores indicate worsening. A decrease in DAS28 score \>1.2 is being referred to as a "good response" and a decrease of 0.6-1.2 as a "moderate response".

    Time frame: Week 14

  2. Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14

    The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). HAQscore on a scale ranges from 0 (no disability) to 3 (completely disabled). Higher scores indicate worsening.

    Time frame: Week 14

  3. Proportion of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24

    An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm) b. Participant's global assessment of disease activity by VAS (0-10 cm) c. Physician's global assessment of disease activity by VAS (0-10 cm) d. Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.

    Time frame: Week 24

  4. Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24.

    Total vdH-S score is sum of joint erosion score and joint-space narrowing (JSN) score. Joint erosion score summarizes erosion severity in 32 joints of hands and 12 joints of feet. Each joint scored from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Maximal erosion score is 280. JSN score summarizes severity of JSN in 30 joints of hands and 12 joints of feet. Assessment of JSN, including subluxation, is scored from 0 (normal) to 4 (bony ankylosis or complete luxation). Maximal JSN score is 168. Thus, the worst possible vdH-S score is 448.

    Time frame: Week 24

07

Results

Posted Oct 14, 2013

Participant flow

This study evaluated the efficacy and safety of intravenous administration of Golimumab 2mg/kg + methotrexate (MTX) in patients with Active Rheumatoid Arthritis despite treatment with MTX therapy. It was conducted between 14 September 2009 and 08 February 2013 and recruited participants at 92 sites in 13 countries worldwide.

Participant flow — Overall Study
MilestoneGroup I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)
Started197395
Completed160326
Not completed3769
Withdrew: Lost to follow-up03
Withdrew: Death22
Withdrew: Withdrawal by subject1516
Withdrew: Lack of efficacy57
Withdrew: Adverse event1232
Withdrew: Protocol violation22
Withdrew: Other17

Outcome measures

PrimaryProportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14

An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 20 percentage improvement in at least 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS), (0 \[no pain\] to 10 \[worst pain\]) b. Participant's global assessment of disease activity by VAS c. Physician's global assessment of disease activity by VAS d. Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C-reactive protein.

Time frame:
Week 14
Reported as:
Number · Percentage of Participants
Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14
Percentage of ParticipantsGroup I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)
Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 1424.958.5
Statistical analysis
  • Group I: Placebo + Methotrexate (MTX) vs Group II: Golimumab 2 mg/kg + Methotrexate (MTX) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryProportion of Participants With Moderate or Good Response in Disease Activity Index Score 28 (DAS28) Using C-reactive Protein (CRP) at Week 14

DAS28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis combining tender joints (28 joints), swollen joints (28 joints), CRP, and participant's global assessment of disease activity. The DAS28 score ranges from 0 (best) to 10 (worst). DAS28 score above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. Higher scores indicate worsening. A decrease in DAS28 score \>1.2 is being referred to as a "good response" and a decrease of 0.6-1.2 as a "moderate response".

Time frame:
Week 14
Reported as:
Number · Percentage of Participants
Proportion of Participants With Moderate or Good Response in Disease Activity Index Score 28 (DAS28) Using C-reactive Protein (CRP) at Week 14
Percentage of ParticipantsGroup I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)
Proportion of Participants With Moderate or Good Response in Disease Activity Index Score 28 (DAS28) Using C-reactive Protein (CRP) at Week 1440.181.3
Statistical analysis
  • Group I: Placebo + Methotrexate (MTX) vs Group II: Golimumab 2 mg/kg + Methotrexate (MTX) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryChange From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14

The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). HAQscore on a scale ranges from 0 (no disability) to 3 (completely disabled). Higher scores indicate worsening.

Time frame:
Week 14
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14
Scores on a scaleGroup I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 140.1250 ± 0.557700.5000 ± 0.57706
Statistical analysis
  • Group I: Placebo + Methotrexate (MTX) vs Group II: Golimumab 2 mg/kg + Methotrexate (MTX) · ANOVA of van der Waerden scores · p = <0.001
SecondaryProportion of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24

An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm) b. Participant's global assessment of disease activity by VAS (0-10 cm) c. Physician's global assessment of disease activity by VAS (0-10 cm) d. Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24
Percentage of ParticipantsGroup I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)
Proportion of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 2413.234.9
Statistical analysis
  • Group I: Placebo + Methotrexate (MTX) vs Group II: Golimumab 2 mg/kg + Methotrexate (MTX) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryChange From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24.

Total vdH-S score is sum of joint erosion score and joint-space narrowing (JSN) score. Joint erosion score summarizes erosion severity in 32 joints of hands and 12 joints of feet. Each joint scored from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Maximal erosion score is 280. JSN score summarizes severity of JSN in 30 joints of hands and 12 joints of feet. Assessment of JSN, including subluxation, is scored from 0 (normal) to 4 (bony ankylosis or complete luxation). Maximal JSN score is 168. Thus, the worst possible vdH-S score is 448.

Time frame:
Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24.
Scores on a scaleGroup I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)
Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24.1.09 ± 3.1940.03 ± 1.899
Statistical analysis
  • Group I: Placebo + Methotrexate (MTX) vs Group II: Golimumab 2 mg/kg + Methotrexate (MTX) · ANOVA of van der Waerden scores · p = <0.001

Adverse events

Collected over Adverse events data were collected for the duration of study (100 weeks) and follow-up (12 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 16—11/68 (16.2%)34/68 (50%)
Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 24—17/121 (14%)38/121 (31.4%)
Golimumab 2 mg/kg + MTX—78/395 (19.7%)199/395 (50.4%)
Combined Golimumab—106/584 (18.2%)271/584 (46.4%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventPlacebo + MTX -> Golimumab 2 mg/kg + MTX at Week 16Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 24Golimumab 2 mg/kg + MTXCombined Golimumab
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/680/12110/39512/584
Angina pectorisCardiac disorders1/680/1211/3952/584
Atrial fibrillationCardiac disorders1/680/1211/3952/584
Myocardial infarctionCardiac disorders1/680/1211/3952/584
Sick sinus syndromeCardiac disorders1/680/1210/3951/584
Device related infectionInfections and infestations1/680/1210/3951/584
EndophthalmitisInfections and infestations1/680/1210/3951/584
PneumoniaInfections and infestations1/680/1214/3955/584
ConcussionInjury, poisoning and procedural complications1/680/1210/3951/584
ContusionInjury, poisoning and procedural complications1/680/1210/3951/584
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo + MTX -> Golimumab 2 mg/kg + MTX at Week 16Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 24Golimumab 2 mg/kg + MTXCombined Golimumab
Upper respiratory tract infectionInfections and infestations5/688/12154/39567/584
Rheumatoid arthritisMusculoskeletal and connective tissue disorders9/683/12133/39545/584
Alanine aminotransferase increasedInvestigations8/683/12127/39538/584
HypertensionVascular disorders8/684/12127/39539/584
BronchitisInfections and infestations6/689/12137/39552/584
Aspartate aminotransferase increasedInvestigations5/682/12118/39525/584
HeadacheNervous system disorders5/682/12127/39534/584
NasopharyngitisInfections and infestations3/688/12128/39539/584
PharyngitisInfections and infestations0/687/12126/39533/584
Urinary tract infectionInfections and infestations3/687/12126/39536/584

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)Total
Mean51.4 ± 11.2651.9 ± 12.5551.8 ± 12.13
Sex: Female, Male
Sex: Female, Male(Participants)Group I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)Total
Female157326483
Male4069109
Region of Enrollment
Region of Enrollment(participants)Group I: Placebo + Methotrexate (MTX)Group II: Golimumab 2 mg/kg + Methotrexate (MTX)Total
Argentina285482
Australia369
Columbia122537
Hungary102131
Korea, Republic of41216
Lithuania204464
Malaysia81826
Mexico132538
New Zealand246
Poland3665101
Russian Federation234669
Ukraine325890
United States61723
08

Study locations

91 sites
  • Daytona Beach, Florida, United States
  • Miami, Florida, United States
  • Palm Harbor, Florida, United States
  • Moline, Illinois, United States
  • Wheaton, Maryland, United States
  • Worcester, Massachusetts, United States
  • Lincoln, Nebraska, United States
  • Cincinnati, Ohio, United States
  • Lubbock, Texas, United States
  • Buenos Aires N/A, Argentina
  • Buenos Aires, Argentina
  • Cordoba, Argentina
  • Rosario, Argentina
  • San Juan, Argentina
  • San Miguel De Tucuman, Argentina
  • Santa Fe, Argentina
  • Cairns, Australia
  • Maroochydore, Australia
  • Melbourne, Australia
  • Woodville, Australia
  • Woolloongabba, Australia
  • Antioquia, Colombia
  • Barranquilla, Colombia
  • Bogota, Colombia
  • Cali Valley Del Cauca, Colombia
  • Medellin, Colombia
  • Budapest, Hungary
  • Debrecen, Hungary
  • Eger, Hungary
  • Gyor, Hungary
  • Gyula, Hungary
  • Szombathely, Hungary
  • Veszprem, Hungary
  • Anyang, Korea, Republic of
  • Dae-Gu, Korea, Republic of
  • Daejeon, Korea, Republic of
  • Incheon, Korea, Republic of
  • Pusan, Korea, Republic of
  • Seoul, Korea, Republic of
  • Alytus, Lithuania
  • Kaunas, Lithuania
  • Klaipeda, Lithuania
  • Siauliai, Lithuania
  • Vilnius, Lithuania
  • Georgetown, Malaysia
  • Ipoh, Malaysia
  • Johor Bahru, Malaysia
  • Kota Kinabalu, Malaysia
  • Kuantan, Malaysia
  • Kuching, Malaysia
  • Precinct 7, Malaysia
  • Selangor Darul Ehasan, Malaysia
  • Seremban, Malaysia
  • Guadalajara, Mexico
  • Leon, Mexico
  • Mexico, Mexico
  • Mex, Mexico
  • Monterrey, Mexico
  • Auckland, New Zealand
  • Takapuna Auckland, New Zealand
  • Timaru, New Zealand
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Dzialdowo, Poland
  • Elblag, Poland
  • Katowice, Poland
  • Lublin, Poland
  • Poznan, Poland
  • Sopot, Poland
  • Szczecin, Poland
  • Warszawa, Poland
  • Wloszczowa, Poland
  • Wrocław, Poland
  • Chelyabinsk, Russian Federation
  • Ekaterinburg, Russian Federation
  • Krasnoyarsk, Russian Federation
  • Moscow N/A, Russian Federation
  • Moscow, Russian Federation
  • Petrozavodsk, Russian Federation
  • Saint Petersburg, Russian Federation
  • Saratov, Russian Federation
  • St.Petersburg, Russian Federation
  • Donetsk, Ukraine
  • Ivano-Frankovsk, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Odessa, Ukraine
  • Simferopol, Ukraine
  • Ternopil, Ukraine
  • Vinnitsa, Ukraine
  • Zaporizhzhya, Ukraine
09

References and documents

Publications

  • Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, Zhou Y, Lo KH, Kavanaugh A. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Res Ther. 2022 Mar 21;24(1):73. doi: 10.1186/s13075-022-02753-6. PubMed 35313978 ↗
  • Lee JB, Broadwell A, Fan Y, Hu C, Adedokun OJ, Chakravarty SD, Zhou H, Xu Z, Leu JH. Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis. Clin Ther. 2022 Mar;44(3):457-464.e2. doi: 10.1016/j.clinthera.2022.01.015. Epub 2022 Feb 17. PubMed 35183373 ↗
  • Tesser J, Kafka S, DeHoratius RJ, Xu S, Hsia EC, Turkiewicz A. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those >/= 65 years of age. Arthritis Res Ther. 2019 Aug 20;21(1):190. doi: 10.1186/s13075-019-1968-x. PubMed 31429794 ↗
  • Standish KA, Huang CC, Curran ME, Schork NJ. Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies. Arthritis Res Ther. 2017 May 12;19(1):90. doi: 10.1186/s13075-017-1299-8. PubMed 28494788 ↗
  • Bingham CO 3rd, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME; GO-FURTHER Investigators. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1627-36. doi: 10.1002/acr.22556. PubMed 25623393 ↗
  • Bingham CO 3rd, Weinblatt M, Han C, Gathany TA, Kim L, Lo KH, Baker D, Mendelsohn A, Westhovens R. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. J Rheumatol. 2014 Jun;41(6):1067-76. doi: 10.3899/jrheum.130864. Epub 2014 May 1. PubMed 24786931 ↗
  • Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, Noonan L, Lu J, Xu Z, Leu J, Baker D, Bingham CO; GO-FURTHER investigators. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis. 2014 Dec;73(12):2152-9. doi: 10.1136/annrheumdis-2013-203742. Epub 2013 Sep 3. PubMed 24001888 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Mar 2011 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 2 years 7 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2009
First posted
Sep 9, 2009
Start
Sep 2009
Primary completionActual
Mar 2011
CompletionActual
Feb 2013
Results delay requested
Mar 12, 2012
Results first posted
Oct 14, 2013
Last update
Dec 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00973479
Lead sponsor
Centocor, Inc.
Collaborators
Schering-Plough
Responsible party
Sponsor
First posted
Sep 9, 2009
Start date
Sep 2009
Primary completion
Mar 2011
Completion
Feb 2013
Results posted
Oct 14, 2013
Last update
Dec 25, 2013

Study contacts

Centocor, Inc. Clinical Trial
study director · Centocor, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Golimumab · Methotrexate

Start the discussion